Navigation Links
Nutra Pharmaceutical's U.S. distributor, XenaCare Holdings Announces National Print Advertising Campaign for Cobroxin, a Treatment for Moderate to Severe (Stage 2) Pain
Date:9/4/2009

Nutra Pharmaceutical's U.S. distributor, XenaCare Holdings announced that its national print advertising campaign for Cobroxin, the first clinically proven, over-the-counter treatment for moderate to severe (stage 2) chronic pain, is scheduled to begin in November and will run in Arthritis Today, Prevention, Health, Star, Woman's World, Soap Opera, and Self Magazines.

(Vocus) September 4, 2009 -- Cobroxin, which was developed by Nutra Pharma Corporation (OTCBB: NPHC), is the first opiate and acetaminophen-free pain reliever available as an over-the-counter formulation that is clinically proven to treat moderate to severe (Stage 2) chronic pain. In August, Nutra Pharma granted XenaCare Holdings the exclusive license for marketing and distributing Cobroxin throughout the United States.

XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that it will begin its national print advertising campaign for Cobroxin in November. The campaign, which is budgeted at approximately $550,000, is scheduled to run through December and will appear in Arthritis Today, Prevention, Health, Star, Woman's World, Soap Opera, and Self magazines.

“This advertising campaign represents the first of several national campaigns we plan to roll out as we introduce Cobroxin through national retailers in the coming months,” explained Frank Rizzo, President of XenaCare Holdings, Inc. “In addition to print advertising, we are also finalizing online marketing campaigns and television commercials,” he concluded.

http://www.UndiscoveredEquities.com

http://nutrapharma.com

http://undiscoveredequities.com/disclaimer_np.html

###

Read the full story at http://www.prweb.com/releases/2009/nphc/prweb2832734.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business
2. Industry Expert Reveals Cutting Edge Biotechnology Science for Nutraceutical and Functional Food Applications
3. EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology
4. NutraCea Appoints New Chief Financial Officer
5. Synutra Announces Postponement of Proposed Offering
6. Eniva VIBE(R) Nutraceutical Tested at Linus Pauling Micronutrient Research Institute and Found to Possess DNA Protective Properties
7. Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited
8. Lixte Biotechnology Holdings Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models
9. Excalibur International Marine (49% Owned by EFT BioTech Holdings) Completes Inaugural Passenger Crossing of Taiwan Strait
10. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Second Quarter 2009 Results
11. EFT BioTech Holdings, Inc.s Sea Vessel Completes Inaugural Passenger Voyage Across the Taiwan Strait
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Nutra Pharmaceutical's U.S. distributor, XenaCare Holdings Announces National Print Advertising Campaign for Cobroxin, a Treatment for Moderate to Severe (Stage 2) Pain
(Date:1/20/2017)... , Jan. 20, 2017 Ginkgo Bioworks, ... Gen9, a pioneer in the synthesis and assembly ... expertise in assembling pathway-length synthetic DNA into Ginkgo,s ... capacity in the construction of new organism designs ... "Gen9 was founded to significantly increase ...
(Date:1/19/2017)... 2017  Market Research Future has a half cooked research report ... is growing rapidly and expected to reach USD 450 Million by ... ... Market has been assessed as a swiftly growing market and expected ... the coming future. There has been a tremendous growth in the ...
(Date:1/19/2017)... , ... January 19, 2017 ... ... advanced software solutions for pharmaceutical research and development (R&D), today announced the ... omic data analysis and interpretation for the rapidly evolving field of precision ...
(Date:1/19/2017)... Mass. , Jan. 19, 2017 AquaBounty ... focused on enhancing productivity in aquaculture and a majority-owned ... announces that it has completed the listing of its ... the equity subscription from Intrexon. "AquaBounty,s listing ... that will broaden our exposure to the U.S. markets ...
Breaking Biology Technology:
(Date:12/15/2016)... Dec. 15, 2016   WaferGen Bio-systems, Inc. ... technology company, announced today that on December 13, 2016, ... of The Nasdaq Stock Market LLC which acknowledged that, ... of WaferGen,s common stock had been at $1.00 or ... regained compliance with Listing Rule 5550(a)(2) of the Nasdaq ...
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in ... biometrics market" The mobile biometrics market is expected to ... 49.33 billion by 2022, at a CAGR of 29.3% ... factors such as the growing demand for smart devices, ... transactions. "Software component is expected to grow ...
(Date:12/7/2016)... 2016 According to a new market research report "Emotion ... Expression, Voice Recognition), Service, Application Area, End User, And Region - Global Forecast ... USD 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at a ... Reading ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):